ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

Despite the initial benefits of treating HER2-amplified breast cancer patients with the tyrosine kinase inhibitor lapatinib, resistance inevitably develops. Here we report that lapatinib induces the degradation of the nuclear receptor ERRα, a master regulator of cellular metabolism, and that the exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Deblois, Geneviève, Smith, Harvey W., Tam, Ingrid S., Gravel, Simon-Pierre, Caron, Maxime, Savage, Paul, Labbé, David P., Bégin, Louis R., Tremblay, Michel L., Park, Morag, Bourque, Guillaume, St-Pierre, Julie, Muller, William J., Giguère, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945959/
https://www.ncbi.nlm.nih.gov/pubmed/27402251
http://dx.doi.org/10.1038/ncomms12156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945959/
https://www.ncbi.nlm.nih.gov/pubmed/27402251
http://dx.doi.org/10.1038/ncomms12156

Ejemplares similares